Tech Company Financing Transactions
Cold Genesys Funding Round
Cold Genesys, based in ?Irvine, secured $10 million from Ally Bridge Group, WI Harper and Song Hong Fang.
Transaction Overview
Company Name
Announced On
8/6/2015
Transaction Type
Venture Equity
Amount
$10,000,000
Round
Series B
Investors
Ally Bridge Group (Lead Investor) (Arthur Kuan)
WI Harper (Lead Investor) (Peter Liu)
Proceeds Purpose
The insider-initiated $10 million Series B financing will advance Cold Genesys' investigational oncolytic immunotherapy CG0070 in a pivotal study (BOND II) that is currently enrolling 122 patients with high-risk non-muscle invasive bladder cancer (NMIBC) who have failed first-line BCG therapy. In addition, proceeds from this financing will be used to develop the combination of CG0070 with immune checkpoint modulators in multiple Phase I/II studies for different solid tumor indications.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
400 Spectrum Center Dr. 2040
?Irvine, CA 92618
USA
?Irvine, CA 92618
USA
Phone
Undisclosed
Website
Email Address
Overview
Cold Genesys, Inc., a clinical-stage biopharmaceutical company developing oncolytic immunotherapies for cancer.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Arthur Kuan
Chief Scientific Officer
Paola Grandi
Controller
Amy Steele
VP - Bus. Development
Bing Kung
VP - Manufacturing
Bradley Grimm
Browse more venture capital transactions:
Prev: 8/6/2015: IncludeFitness venture capital transaction
Next: 8/6/2015: Zest Health venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records on this site are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs